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Precision monitoring of antibody responses during the COVID-19 pandemic is increasingly
important during large scale vaccine rollout and rise in prevalence of Severe Acute
Respiratory Syndrome-related Coronavirus-2 (SARS-CoV-2) variants of concern (VOC).
Equally important is defining Correlates of Protection (CoP) for SARS-CoV-2 infection and
COVID-19 disease. Data from epidemiological studies and vaccine trials identified virus
neutralising antibodies (Nab) and SARS-CoV-2 antigen-specific (notably RBD and S)
binding antibodies as candidate CoP. In this study, we used the World Health
Organisation (WHO) international standard to benchmark neutralising antibody
responses and a large panel of binding antibody assays to compare convalescent sera
obtained from: a) COVID-19 patients; b) SARS-CoV-2 seropositive healthcare workers
(HCW) and c) seronegative HCW. The ultimate aim of this study is to identify biomarkers of
humoral immunity that could be used to differentiate severe from mild or asymptomatic
SARS-CoV-2 infections. Some of these biomarkers could be used to define CoP in further
serological studies using samples from vaccination breakthrough and/or re-infection
cases. Whenever suitable, the antibody levels of the samples studied were expressed in
International Units (IU) for virus neutralisation assays or in Binding Antibody Units (BAU) for
ELISA tests. In this work we used commercial and non-commercial antibody binding
assays; a lateral flow test for detection of SARS-CoV-2-specific IgG/IgM; a high throughputorg November 2021 | Volume 12 | Article 7482911
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Frontiers in Immunology | www.frontiersin.multiplexed particle flow cytometry assay for SARS-CoV-2 Spike (S), Nucleocapsid (N) and
Receptor Binding Domain (RBD) proteins); a multiplex antigen semi-automated immuno-
blotting assay measuring IgM, IgA and IgG; a pseudotyped microneutralisation test (pMN)
and an electroporation-dependent neutralisation assay (EDNA). Our results indicate that
overall, severe COVID-19 patients showed statistically significantly higher levels of SARS-
CoV-2-specific neutralising antibodies (average 1029 IU/ml) than those observed in
seropositive HCW with mild or asymptomatic infections (379 IU/ml) and that clinical
severity scoring, based on WHO guidelines was tightly correlated with neutralisation and
RBD/S antibodies. In addition, there was a positive correlation between severity, N-
antibody assays and intracellular virus neutralisation.Keywords: COVID-19, SARS-CoV-2, Serological biomarkers, Antibodies, WHO International Standard, Correlates of
Protection, COVID-19 immune response1 INTRODUCTION
From the moment the World Health Organisat ion
(WHO) declared COVID-19 a Public Health Emergency of
International Concern (1), SARS-CoV-2 continued its global
spread and caused more than 3 million deaths up to April 2021
(2). A total of 184 candidate vaccines are now in pre-clinical
development and 92 have entered the clinical phase. Of the latter,
seven vaccines have been approved by National Regulatory
Authorities in different parts of the world and WHO have
issued Emergency Use Listing for four of these (3). All these
developments occurred in less than a year, thanks to the
unprecedented joint effort made by the scientific community,
WHO and other international public-health entities, the
pharmaceutical Industry and philanthropic organisations.
Because a defined Correlate of Protection (CoP) to COVID-19
did not exist, and still remains elusive, the efficacy of these
vaccines was evaluated in large placebo-controlled clinical trials
involving large numbers of participants exposed naturally to
SARS-CoV-2 in countries that had active COVID-19 epidemics
(4). Though successful, this process was very costly and
logistically demanding. The last few months of the pandemic
are being characterised by the emergence of SARS-CoV-2
variants that carry mutations that resulted in increased
transmissibility, increased pathogenicity or increased potential
to evade the immune response of the host (5). Determining the
vaccine efficacy against these variants of concern (VOC) is of
high priority for regulatory bodies and vaccine manufacturers in
the coming months or perhaps years.
In the absence of a universally accepted CoP against COVID-
19, data from Phase III clinical trials suggested that virus
neutralising antibodies (nAb) are a candidate CoP (6).
Likewise, observations made on the natural history of COVID-
19 indicated the association of nAb and protection (7). However,
the protective threshold for nAb has been difficult to establish in
different settings. Early studies comparing clinical progression
and case fatality rates found that the magnitude of the antibody
response correlated with the severity of disease (8–10). Patients
with fatal outcomes often had the strongest IgG responses to
nucleoprotein (N), and were often accompanied by markedorg 2responses to the Spike (S) protein (11). Furthermore, patients
with severe disease have also been reported to have high nAb
titres (12, 13), with studies showing a strong correlation between
live-virus or pseudotype based micro-neutralisation (pMN) and
anti-Spike antibody binding assays (10, 14).
Cellular immune responses directed against internal viral
antigens often play an important role in the clearance of viral
infections. The effector mechanisms of anti-viral immunity of
non-neutralising antibodies are becoming better understood (15,
16) and it is often that these are directed against viral internal
antigens, such as the N antigen of SARS-CoV-2. One of these
mechanisms is mediated by the cytosolic antibody receptor
TRIM21 (17), which captures antibody-antigen complexes and
accelerates their degradation and processing through the
proteasome, facilitating the loading of antigenic peptides in
nascent MHC molecules and promoting antigen presentation
to T cells (18). While the latter study focused on antibodies
against the nucleoprotein of the enveloped positive strand RNA
virus LCMV, it is possible that antibodies directed against the N
antigen of SARS-CoV-2 function in a similar way. We therefore
analysed TRIM21-mediated biomarkers of immunity in our
cohorts using established methods (19) to determine the
holistic role of antibodies in protection from COVID-19 disease.
One of the factors that have precluded the derivation of well-
defined humoral CoP in general, and to COVID-19 disease in
particular, is the diverse number of quantitative antibody assays
available and the different units used to quantify the antibody
levels of clinical samples. Measuring nAb against SARS-CoV-2 is
typically done by virus neutralisation tests such as plaque
reduction neutralisation test (PRNT), infectious centre assays
or micro-neutralisation tests (20–24). These are performed with
live SARS-CoV-2 or with pseudotyped viruses (typically
lentivirus or vesicular stomatitis virus) displaying SARS-CoV-2
Spike protein in their envelope. The antibody levels of these
assays are quantified in serum titres for specific percentages of
neutralisation (i.e. PRNT50, PRNT80), or as IC50 or other
readouts. The choice of antibody binding assays is also varied,
from the traditional ELISA format to more refined commercial
assays (ECLIA, multiplexed micro-sphere assays, semi-
automated immunoblotting assays). These methods use theNovember 2021 | Volume 12 | Article 748291
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as target antigens. The readouts of these assays are expressed
using a diverse suite of units such as antibody titre, OD (optical
density) values for specific wave lengths (450 nm, 490 nm) or
mean fluorescent intensity (MFI) units or Chemiluminescent
units (MCI). In order to harmonise results of quantitative
COVID-19 immuno-assays, the WHO has advocated the
use of the ‘International Standard for SARS-CoV-2
immunoglobulin’ (NIBSC code ‘20/136’) as a primary assay
calibrant (25, 26). We used this reagent and its assigned
unitage (1000 units/ml) as a reference to derive, in
International Units (IU), the potency of our ‘in-house’ internal
assay calibrants. In this way, antibody levels of samples tested by
either neutralisation of antibody binding assays can be expressed
in IU or Binding Antibody Units per ml (BAU/ml) and thus
immunogenicity and vaccine efficacy data can be compared
between different laboratories.
The Humoral Immune Correlates for COVID-19 Project
(HICC) aims to dissect the humoral immune response to
SARS-CoV-2 and identify the mechanisms of immunity that
protect from COVID-19 and to distinguish them from pro-
inflammatory and complement responses leading to severe
disease. The specific aim of the present study is to define
antibody-based biomarkers that differentiate severe from mild/
asymptomatic COVID-19 cases. These antibody based
parameters can also be used to define CoP in vaccine
breakthrough and/or re-infection studies. Wherever possible,
we expressed these antibody measurements in IU or BAU.
Towards this objective, we have analysed the antibody levels
and antigenic specificity of convalescent antibody samples of
HCWs and hospitalised COVID-19 patients exposed and
infected during the first pandemic wave (between March 2020
– October 2020) in the UK. This study defines the methods and
findings establishing a benchmark for future longitudinal studies
to define COVID-19 CoP.2 MATERIALS AND METHODS
2.1 Selection of Sera and Plasma
Serum and plasma samples were obtained from healthcare
workers (HCW) and patients referred to the Royal Papworth
Hospital, Cambridge, UK for critical care. COVID-19 patientsFrontiers in Immunology | www.frontiersin.org 3hospitalised during the first wave and as well as NHS healthcare
workers working at the Royal Papworth Hospital in Cambridge,
UK, served as the exposed HCW cohort (Study approved by
Research Ethics Committee Wales, IRAS: 96194 12/WA/0148.
Amendment 5). NHSHCWparticipants from the Royal Papworth
Hospital were recruited through staff email over the course of two
months (20th April 2020-10th June 2020) as part of a prospective
study to establish seroprevalence and immune correlates of
protective immunity to SARS-CoV-2. Patients were recruited in
convalescence either pre-discharge or at the first post-discharge
clinical review. All participants provided written, informed
consent prior before enrolment in the study. Sera from NHS
HCW and patients were collected between July and September
2020, 3-5 months after they were enrolled in the study.
Clinical assessment and WHO criteria scoring of severity for
both patients and NHS HCW (Table 1) was conducted following
the ‘COVID-19 Clinical Management: living guidance’ (27).
For cross-sectional comparison, representative convalescent
serum and plasma samples were collected from seronegative
HCWs, seropositive HCW and convalescent PCR-positive
COVID-19 patients. The serological screening to classify
convalescent HCW as positive or negative was done according
to the results provided by a UKAS-accredited Luminex assay
detecting N-, RBD- and S-specific IgG, a lateral flow diagnostic
test (IgG/IgM) and an Electro-chemiluminescence assay
(ECLIA) detecting N- and S-specific IgG. Any sample that
produced a positive result by any of these assays was classified
as positive. The severity score of the individuals from which the
sample was obtained ranged from 0 to 7 according to the WHO
classification described above. Thus, the panel of convalescent
serum samples (3-5 months post-infection) were grouped in
three categories: a) Patients (n=38); b) Seropositive HCW (n=24
samples); and c) Seronegative HCW (n=39) (Table 2).
2.2 Internal and External Calibration
Reagents
The reference reagents used as external, or primary calibrants in
our assays included: a) the First WHO International Standard for
anti-SARS-CoV-2 immunoglobulin (NIBSC 20/136); b) the
Anti-SARS-CoV-2 Antibody Diagnostic Calibrant (NIBSC 20/
162; and c) the Research Reagent for anti-SARS-CoV-2 Ab
(NIBSC 20/130). Details of these are described in the NIBSC





2 Mild Disease Case definition without of COVID-19 without pneumonia
3 Moderate pneumonia Fever, cough, dyspnoea, SpO2 >90%
4 Severe pneumonia Fever, dyspnoea, cough plus RR>30, SpO2 <90%requirement;
5 ARDS (Acute Respiratory Distress
Syndrome)
diffuse bilateral infiltrates PaO2/FiO2<300
6 Sepsis Life-threatening organ disfunction: severe dyspnoea, delirium, low O2 saturation, oliguria, tachycardia, weak pulse,
low blood pressure, coagulopathy
7 Septic Shock As above plus Vasopressor requirementNovember 2021 | Volume 12 | Article 748291
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unitage of tested samples and/or to calibrate our own Internal (or
secondary) assay calibrants. The latter were obtained from NHS
healthcare workers exposed to SARS-CoV-2. Thus, HICC
Serum-1 and HICC Serum-2 were pooled serum samples
collected from RT-PCR-confirmed SARS-CoV-2-infected NHS
personnel 2 months after presenting moderate symptoms of
COVID-19.
2.3 Pre-Pandemic Plasma
A panel of 23 pre-pandemic plasma collected between 2016 and
2019, obtained from the National Institute of Biological
Standards and Control (NIBSC), was used to set up the
negative cut-off point of the quantitative immunoblotting
assay, the pan-Ig N- and RBD-ELISA and the pMN assays.
2.4 Detection of Total Antibody (Pan-Ig)
Against SARS-CoV-2 Spike (S) and
Nucleocapsid (N) Antigens by ELISA
Two different ELISA tests were used for the detection of N-
specific and S-specific antibodies. The assays were adapted from
those originally described by Amanat and co-workers (29).
Briefly, Nunc MaxiSorp™ flat-bottom plates were coated with
50 ml per well of 1 mg/ml of either RBD or N antigen in DPSB
(-Ca2+/-Mg2+) and incubated overnight at 4°C. The next day, the
plates were blocked with 3% milk in PBST (0.1% w/v Tween20 in
PBS) for 1 hour. After removing the blocking buffer, 50 ml/well of
serum samples, diluted in PBST-NFM (1% w/w non-fat milk in
PBST) were added to the plates and incubated on a plate shaker
for two hours at 20°C. The plates were washed three times with
200 ml of PBST, and 50 ml of HRP-conjugated goat anti-human
Ig (H and L chains) (Jackson ImmunoResearch) diluted 1:3000
in PBST was added to each well and left to incubate for one hour
on a plate shaker for 1 hour. Plates were washed three times with
200 ml of PBST and 50 ml/well of 1-Step Ultra TMB chromogenic
substrate (Sigma) were added to the plates and the chemicalFrontiers in Immunology | www.frontiersin.org 4reaction was stopped three minutes later with 50 ml 2N H2SO4.
The optical density at a wavelength of 450 nm (OD450) was
measured using a Biorad microplate reader.
All test runs included, in addition to the test sample dilutions,
an internal calibrant dilution series (HICC Serum 2), a single
dilution of a positive control per plate (NIBSC 20/130), a
negative control sample (NIBSC 15/288) per plate and a blank
control (no primary antibody or sample). All samples were tested
in duplicate and the duplicate readings were used to fit the
standard curve. The blank readings were subtracted from the
serum sample values. The IC50 values of each sample dilution
series were determined and expressed as relative potency respect
to the Internal Calibrant, for which a unitage in ELISA binding
units was calculated using the WHO International Standard 20/
136 as a reference. Details of how these were calculated are




Samples were tested on Roche cobas® e801 analyser at PHE
Porton Down. Anti-nucleocapsid protein antibodies were
detected using the qualitative Roche Elecsys® Anti-SARS-CoV-
2 (ACOV2) ECLIA (Product code: 09203079190), whilst anti-
RBD antibodies were detected using the quantitative Roche
Elecsys® Anti-SARS-CoV-2 S (ACOV2 S) ECLIA (Product
code 092892751902), as previously described (30, 31). Both
assays detect total antibodies (IgG, IgA and IgM). All kits were
calibrated based on a two-point calibration curve according to
the manufacturer’s instructions, with daily QC performed per
reagent pack. Anti-NP results are expressed as a cut-off index
(COI) value, with a COI ≥1 interpreted as positive. Anti-spike
results are expressed as units per ml (U/ml), with results of ≥ 0.8
U/ml interpreted as positive and a quantitative range of 0.4 to
2,500 U/ml.
2.6 Detection of SARS-CoV-2-S, -RBD and
-N specific Antibodies Using a Multiplex
Bead Flow Cytometry Platform,
Luminex™ Platform
Detection of serum IgG reactive to SARS-CoV-2 N, S and RBD
(receptor binding domain) antigens was done using a Luminex
based assay following the methods previously described (32, 33).
The amino acid sequences used derived from the S ectodomainTABLE 2 | Cohorts. Classification of participants according to the serological screening of the sera by the ECLIA, multiplex Micros-sphere, and lateral flow assays.
Assay Platform Antigen/Isotype Patients Seropositive Staff Seronegative Staff
Pos. Neg. ND Pos. Neg. ND Pos. Neg. ND
Luminex N 36 2 0 22 2 0 0 38 1
S 36 2 0 19 5 0 0 38 1
RBD 36 2 0 18 6 0 0 38 1
Roche RBD 34 2 2 18 6 0 0 36 3
N 34 2 2 18 6 0 0 36 3
Lateral Flow IgG 35 2 1 20 4 0 0 39 0
IgM 19 15 1 15 9 0 0 39 0November 2021 | Volume 12 | Article 74TABLE 1B | Cohort demographic and severity score classification.
Symptom Severity Score
1 2 3 4 5 6 7
Patients 2 3 0 15 1 2 15
HCW-P 4 12 8 0 0 0 0
HCW-N 22 13 3 0 0 0 08291
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samples were tested in duplicate and all test runs included a
serum positive control, a serum negative control, and BSA and
LPS antigen controls as blanks. Results outputs were expressed in
MFI units. A machine training algorithm was used to assign a final
serological classification to all the samples studied, as described
previously (33). This method assigns a SARS-CoV-2 serological
status considering the values the IgG values (MFI) for the three
antigens. The negative cut off values for N-, RBD- and S-specific
IgG assays were set up at 1604, 456 and 1896 respectively.
2.7 SARS-CoV-2 Pseudotype-Based
Microneutralisation Assay (pMN)
Virus neutralising antibodies were detected and quantified by a
pseudotype-based neutralisation assay based on a lentiviral
system that enables the generation of replication-defective
recombinant human immunodeficiency virus (HIV) displaying
the Spike protein of SARS-CoV-2 on their viral envelope, as
previously described (34, 35). Briefly, HEK293T cells were seeded
in 10 cm2 cell culture dishes at a density to achieve 70%
confluency after 24 hours for next day transfection. HEK293T
cells were maintained in DMEM (Dulbecco Minimum Essential
Medium) containing 10% foetal bovine serum and 1% penicillin/
streptomycin, at 37°C and 5% CO2. Cell maintenance was done
by three cell passages per week.
On the day of transfection, the culture medium was replaced
with fresh complete DMEM. Cells were transfected with 1000 ng
of pcDNA-SARS-CoV-2 Spike plasmid, 1000ng of HIV 8.91 gag/
pol plasmid and 1500ng of pCSFLW luciferase plasmid, using
FuGENE HD (Promega, UK), at a 1:3 ratio (plasmid:FuGENE
HD). The culture media was harvested 48 hours post-
transfection and filtered through a 0.45μm filter. The filtered
pseudotype virus (PV) was aliquoted, titrated and stored at
-80°C. Titration of PVs was carried out in a 96 well white plate
typically using doubling serial dilutions. Pre-transfected
HEK293T target cells expressing human ACE2 and TMPRSS2
were seeded at 104 cells per well and plates were incubated for 48
hours prior to the addition of Bright-Glo reagent (Promega, UK)
and reading the result in a luminometer.
For detecting and quantifying neutralising antibodies, serial
doubling dilutions of the plasma samples in complete DMEM
were performed from an initial 1/40 dilution. SARS-CoV-2 PVs
were added at 5x105 – 5x106 RLU/ml in each well and the plates
incubated for 1 hour in at 37°C, 5% CO2 incubator. Post
incubation, pre-transfected HEK293T target cells expressing
human ACE2 and TMPRSS2 were seeded at 104 cells per well
and plates were incubated for 48 hours prior to the addition of
Bright-Glo reagent and assaying using a luminometer.
In addition to the test sample dilutions, all test runs included
dilution series of an external calibrant (NIBSC 20/162) or an
internal calibrant (HICC Serum 2) and a single dilution of a
positive control per plate (NIBSC 20/130). All samples were
tested in duplicate and the average of the OD values determined.
The IC50 values of each sample dilution series were determined
and expressed as relative potency respect to the Internal or
External Calibrant which enabled the expression of results
in International Units using the WHO International StandardFrontiers in Immunology | www.frontiersin.org 520/136 as a primary calibrator. Details of how these were
calculated are described in the ‘Results’ section.
2.8 Semi-Automated Immunoblotting
Plasma IgG antibodies reactive against the SARS-CoV-2 Spike
and Nucleocapsid proteins were analysed by immuno-blotting
using the ‘Jess’ fully automated system (ProteinSimple; Bio‐
Techne) and the SARS-CoV-2 Multi-Antigen Serology Module
(ProteinSimple; Bio-Techne, SA-001), following the
manufacturer’s instructions. Here, the 12–230 kDa Jess/Wes
Separation Module was used. Briefly, the kit provides five
SARS-CoV-2 recombinant viral antigens: RBD, N, S1 subunit,
S2 subunit and S (S1+S2). The antigens were electrophoretically
separated according to their molecular weight to create a ladder
for capture of reactive antibodies. Two microlitres of plasma
samples diluted 1:10 in diluent buffer were loaded. For the
secondary antibody, ready to use HRP‐conjugated goat anti‐
human IgG, IgA or IgM antibody was used. Digital image of
chemiluminescence of the capillary was captured with the
Compass Simple Western software (version 4.1.0, Protein
Simple), that automatically calculated chemiluminescence
intensity of each single antigen binding signal. Results could be
visualized as electropherograms representing peak of
chemiluminescence intensity and as lane view from signal of
chemiluminescence detected in the capillary. To control for
differences in signal between experiments, a reference sample,
the NIBSC Anti-SARS-CoV-2 Antibody Diagnostic Calibrant
(NIBSC 20/162) was included in each experiment. A panel of
pre-pandemic plasma sera was used to calculate the negative cut-
off value for each of the antigen tests (mean + 2STD). Final
results of the samples were calculated by subtracting the negative
cut-off value from the chemiluminescent signal of the sample.
2.8 Lateral Flow IgG/IgM
A rapid detection kit (Accu-Tell COVID-19 IgG/IgM Antibody
Test) for SARS-CoV-2 was used following manufacturer’s
instructions and compared with other antibody detection
platforms. Briefly, 5μl of heat-inactivated serum were added to
the antigen test cassettes followed by 2 drops of the supplied PBS.
After an incubation of 30 min at 20°C, the results were recorded.
A positive IgG or IgM result was indicated by the appearance of a
band for either of the isotypes included in the assay. Tests were
valid only if a control band appeared in the device.
2.9 Electroporation-Dependent
Neutralisation Assay (EDNA)
Electroporation was performed using the Neon Transfection
System (Thermo Fisher). Vero ACE2/TMPRSS2 cells (36) were
washed with PBS and resuspended in Buffer R (Thermo Fisher) at
a density of 1 x 106 cells per ml. For each electroporation reaction
0.5 x 106 cells (10.5 μl) were mixed with 2μl of serum to be
delivered. The mixture was taken up into a 10 μl Neon Pipette Tip
and electroporated using the following settings: 1400V, 20ms, 2
pulses. Electroporated cells were transferred to medium
supplemented with 10% serum without antibiotics. 1.5 x 104
electroporated cells were seeded into 96-well plates in triplicates
and after 24h transferred to containment level 3 laboratory.November 2021 | Volume 12 | Article 748291
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remove any remaining antibodies that could interfere with virus
entry. Cells were infected at moi = 1 in DMEM supplemented with
2% FBS and antibiotics and incubated for 24h to allow for a single
replication cycle. The virus used was a derivative of the Wuhan
virus, SARS-CoV-2/human/Liverpool/REMRQ0001/202, isolated
by Lance Turtle (University of Liverpool) and David Matthews
and Andrew Davidson (University of Bristol). After incubation,
plates were immediately frozen at -70°C to help with cell lysis.
Next, plates were thawed at 4°C and 1 volume of lysis buffer
(0.25% Triton-X100, 50mM KCl, 100mM Tris-HCl pH 7.4,
glycerol 40% and RNAsecure from Invitrogen at 1/100) was
added to wells and mixed gently by pipetting. After 5min of
lysis, cell lysates were transferred to PCR plates and virus
inactivated at 95°C for 5min. RT-qPCR was performed with
Luna® Universal Probe One-Step kit (E3006, NEB) following
manufacturer recommendations. Primer/probe for genomic viral
RNA were CDC-N2 (IDT 2019-nCoV RUO kit). Primer probe for
18S control were described previously (37). SARS-CoV-
2_N_Positive control RNA from IDT (10006625) was used as
standard for the viral genomic N reactions. For 18S rRNA
standard, DNA was synthesized and kindly gifted by Jordan
Clarks and James Stewart (University of Liverpool). Final
concentrations of 500nM for each primer and 125nM for the
probe were used. RT-qPCR reactions were run on ABI
StepOnePlus PCR System (Life Technologies) with following
program: 55°C for 10min, 95°C for 1min and then 40 cycles of
95°C denaturation for 10sec and 60°C extension for 30sec. RNA
copy numbers were obtained from standards and then genomic
copies of N normalised to 1010 copies of 18S. Finally, all data was
normalized to 100% to PBS electroporated cells.
2.10 Statistical Methods
We calculated log IC50 values to summarise the RBD-specific and
N-specific antibodies as measured by ELISA and neutralising
antibody titre as measured by neutralisation. Log IC50 values
were estimated by fitting four parameter log-logistic regression
dose response curves in the R package drc (38). The four
parameters of this curve are the minimum response, the
maximum response, the log of the dilution halfway between
the two (IC50), and the gradient at the IC50. Our models actually
estimated the natural log of IC50 values because it improved
model convergence and produced normally distributed values
for downstream analyses.
To ensure IC50 values were comparable, a single gradient,
minimum, and maximum value was estimated for dose response
curves of all samples. To minimise noise between experimental
runs the gradient, minimum, and maximum parameters were
estimated based on a random subset of 200 samples and fixed for
all other samples. Graphical checks showed that these parameters
produced curves that fit the observed data well. We observed that
this parameter fixing decreased the variance in estimated log IC50
values for calibrants.
Samples and calibrants could be assigned an international
unitage based on their potency relative to the international
standard NIBSC 20/136 which has been assigned an arbitrary
unitage of 1000 IU/ml. Unitage for a sample was expressed asFrontiers in Immunology | www.frontiersin.org 6Units of sample = Calibrant units Sample IC50=Calibrant IC50
In practice, the unitage of calibrants was quantified in
international units as shown above and the unitage of samples
was calculated based on their potency relative to a calibrant with
a known international unitage. The reason for this two-step
process is that the international standard was not available until
December 2020.
To assign international units to the calibrants, these were run
in duplicate alongside the international standard and relative
potencies and international units were calculated as described
above. The assumption of parallel curves was verified by
comparing the AIC of models which allowed separate
gradients to those which did not.
The Spearman’s rank correlation coefficient for variables pairs
and Mann-Whitney U tests were calculated using R (39).
3 RESULTS
The primary objective of this work was to identify relevant
biomarkers of humoral immunity that can serve to differentiate
severe from mild/asymptomatic COVID-19 cases and also could
be used as potential Correlates of Protection (CoP) of COVID-
19. In this study we analysed antibody-based parameters present
in serum or plasma of convalescent patients and compared these
antibody levels to those in seropositive and seronegative health-
care workers (HCW).
3.1 Clinical Details of Patients and
Healthcare Workers Included in this Study
The participants of this study were classified into three cohorts:
a) Patients; b) Seropositive HCW; and c) Seronegative HCW
(Table 2) using the criteria described in the methods section.
Any participant displaying a positive result by any of the
screening tests was considered seropositive. A large proportion of
hospitalised patients (82%) presented a clinical score of 4 (Severe
Pneumonia) (Table 1B). Approximately half of these patients
(47%) presented septic shock or sepsis (clinical scores of 7 and 6),
38% developed ARDS (Acute Respiratory Distress Syndrome) or
severe pneumonia (clinical score 5 and 4) and only two patients
presentedmoderate pneumonia (clinical score 3). Only two patients
were asymptomatic. All patients (but not all HCW) had a positive
PCR diagnostic result and all patients, except two, presented SARS-
CoV-2-specific antibodies. Clinical scores of seropositive HCW
ranged between 1 and 3. A third of these individuals (33%)
presented moderate pneumonia (clinical score of 3), 50% showed
mild disease (clinical score 2) and 12.5% were asymptomatic. In
contrast, the majority of seronegative HCW were asymptomatic
(59%) or presented with symptoms of mild disease (33%) and only
3 individuals presented moderate pneumonia.
3.2 Calibration and Standardisation of
Antibody Assays
Whenever possible, we defined candidate humoral CoP in units
relative to the WHO International Standard. Quantitative
antibody assays (pMN, RBD ELISA, N ELISA) were calibrated
using our internal reference antiserum (HICC S2) or an externalNovember 2021 | Volume 12 | Article 748291
Castillo-Olivares et al. Serological Biomarkers of COVID-19calibrant. At the start of this work, the WHO International
Standard, NIBSC 20/136 had not yet been developed and we
calibrated our internal standard against the NIBSC 20/162
calibrant reagent, which was available at that time. In some
instances, we used the latter reagent directly as our assay
calibrant in the neutralisation (nAb) assay. This reagent,
NIBSC 20/162, was assigned 1000 units for the pMN, the pan-
Ig N and the pan-Ig S assays. The results of the pMN, N-ELISA
and RBD-ELISA, were converted to IU or Binding Antibody
Units (BAU) of the WHO International Standard (NIBSC 20/
136) once the latter became available.
In order to calculate the Unitage of the HICC reference sera
(used as Internal Calibrants), we tested in the same assay serial
dilutions of the HICC reference sera and NIBSC reagents. After
preparing the corresponding calibration curves (Figure 1), we
performed a parallel line analysis. Such analysis supported the
mathematical derivation of a unitage value for our internal
calibrants from the NIBSC 20/162 reagent. Thus, HICC
Serum-2 was assigned a value of 504 BAU/ml for the pan Ig
N-ELISA, 98 BAU/ml for the pan Ig-G RBD ELISA and 76 IU/ml
for the pMN assay. The results of each sample tested by these
assays were expressed in the corresponding units as follows:
Units of sample = (IC50of Test sample=IC50of calibrant)
 unitage of the calibrant
When the WHO International Standard for anti-SARS-CoV-2
immunoglobulin 20/136 became available, the conversion into
International Units (IU) and Antibody Binding Units (BAU)
specific for N-, RBD-, and S- antigens (N-BAU,RBD-BAU, S-
BAU) was calculated by multiplying the values (units) of samples
by a factor F, which is the ratio of the IC50 of NIBSC 20/162
relative to the IC50 of the International Standard 20/136. Thus, all
results of the pMN and the Pan-Ig ELISA tests included in this
study are expressed in IU and BAU relative to the WHO
International Standard, respectively.Frontiers in Immunology | www.frontiersin.org 73.3 Antibody Biomarkers of COVID-19
Immunity as Potential CoP
The convalescent serum or plasma samples from these three
cohorts were analysed by a range of assays that measure
antibody-based biomarkers of immunity: a) a pseudotype-
based microneutralisation assay (pMN); b) a Luminex IgG
assay specific for N, S and RBD; c) a pan-Ig ELISA for N and
RBD; d) a multiplex antigen (S, S1, S2, N and RBD) immuno-
blotting assay for IgG, IgM and IgA; e) a commercial lateral flow
assay for rapid detection of SARS-CoV-2-specific IgG and IgM;
and f) a commercial electrochemiluminescence assay (ECLIA).
We analysed the data of all these assays and determined
individual correlations of all these measurements with one
another and with the clinical severity scores assigned to the
individuals the samples derived from. These analyses
(Figure 2A) showed four main clusters of assay correlations.
The first cluster is represented by IgA Immunoblotting assays for
S, S1, S2 and RBD (Figure 2B). A second group is formed by IgG
assays based on Spike-derived antigens and pMN assay
(Figure 2B). The third cluster is formed by N-specific assays
(Figure 2C). The intracellular neutralisation assay (EDNA)
correlated positively with N-specific IgG and IgA binding
assays. Due to the shorter duration of IgM than IgG and IgA
in blood following a viral infection, it was not surprising that the
IgM assay results of convalescent sera did not show positive or
negative correlations with the IgG, IgA, pMN assays, intracellular
neutralisation or clinical severity. Overall, clinical severity
correlated positively with nAb data, S/RBD, N antibody
binding measurements. As expected, nAb data correlated more
strongly with S-specific and RBD-specific binding antibodies
than with N-specific antibody levels, indicating N-specific
antibodies maybe a good biomarker of previous infection and
its severity but not necessarily the best surrogate of nAb.
Having established the general correlations of the biomarkers
under study in these convalescent samples, we dissected in more
detail the data generated by these assays.A B C
FIGURE 1 | Comparison of internal calibrants and International Standard for neutralization and binding assays. The IC50 from these curves were used to calculate
the (A) International units (IU); (B) RBD-specific Binding Antibody Units (BAU); and (C) N-specific Binding Antibody Units (BAU). Calibrants were run four times at
each dilution for pMN and twice for ELISA tests.November 2021 | Volume 12 | Article 748291
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Responses
The antibody screening assays used to classify the serum samples
from patients and HCW produced concordant results with a few
exceptions. All samples from patients were positive by all three
IgG assays except those from patient 37 and patient 50, which
tested negative by all three assays. These patients were
asymptomatic and their clinical histories revealed that they
were already hospitalised for other conditions before becoming
infected with SARS-CoV-2. Only a small group of seropositive
HCW samples produced discordant results. Thus, HCW s198,
s223, s286, s370, s398 and s423 presented positive results only by
some of the assays but none of these results were strongly
positive. As expected, a proportion of the convalescent samples
from patients and HCW did not test positive by the IgM lateral
flow assay (data not shown).
The samples were classified into the three cohorts by the
screening assays were analysed by the ‘HICC in-house’ pan-Ig
ELISA for RBD and N antigens. The results were largely
consistent with those of the Luminex, lateral flow assay and
ECLIA tests. Only a few discrepancies were noted. Thus, all sero-
negative HCW samples tested negative by the N and RBD pan-Ig
ELISA, except s195, s296 and s269 samples. HCW samples s195
and s196 were positive for RBD, presenting values of 4.4 and 2.5
RBD-BAU/ml respectively, just above the negative cut-off value
(2 RBD-BAU/ml), but were negative by the N ELISA (negative
cut-off value of 4 N-BAU/ml). Sample s269 which had 14.3 N-
BAU/ml (negative cut-off value 7.7 N-BAU/ml) but was negative
for RBD. As expected, all patients’ samples tested positive against
both antigens and presented high values (mean 414.5 RBD-BAU/
ml; mean 316 N-BAU/ml), except patient 37, which tested
negative for both antigens. Patient 50, which tested negative by
all screening serological assays, presented low antibodies to RBDFrontiers in Immunology | www.frontiersin.org 8(20.9 N-BAU/ml) and N (26.3 N-BAU/ml) antigens. Results of
the pan-Ig N and pan-Ig RBD from seropositive HCW were also
in line with the Luminex, lateral flow and ECLIA tests. The
average antibody levels of seropositive HCW, 118.9 RBD-BAU/
ml and 234.6 N-BAU/ml, were significantly lower than those
found in patients (Mann-Whitney U test, RBD: U=717, p<0.001;
N U=630, p=0.006). The same samples that produced conflicting
results by the serological screening assays, namely s198, s223,
s286, s370, s398 and s423, produced very low N- and RBD-
BAU results.
3.5 Virus Neutralising Antibody Responses
Measured by Pseudotype Based Micro-
Neutralisation
The pMN results revealed a significant difference in neutralising
antibody titres (nAb) between the three cohorts (Figure 3). As
expected, the seronegative HCW sera presented very low nAb
(mean 5.3 IU/ml). In contrast, seropositive HCW presented
moderately high nAb levels (mean value 379 IU/ml), whereas
patients presented a three-fold higher level (1029 IU/ml). Of note
is that three seronegative HCW (s38.2, s38.1, s228) had low nAb
but these were above 24.2 IU/ml (mean of negative HCW+
2STD). This pMN value is well above 6 IU/ml, a negative cut-off
value for this assay calculated from a small panel of pre-
pandemic sera (mean + 2SD) suggesting that these individuals
could have been exposed to SARS-CoV-2, despite antibody
binding assays showing negative values for all of them. Five
seropositive HCW samples (s223, s286, s370, s398 and s423) had
nAb below 6 IU/ml, which was consistent with the low values
obtained in the serology screening tests and the pan-Ig ELISA.
All of these individuals were asymptomatic or had mild disease
without pneumonia, except HCW 370 who had moderate
pneumonia. It would be interesting to investigate the frequencyA B C
FIGURE 2 | (A) Correlation plot showing pairwise Spearman’s rank correlation between assays. Darker and larger points indicate stronger correlations. Blue indicates
positive and red indicates negative correlations. Assays are ordered by hierarchical clustering so that assays with similar relationships are together. (B) Correlation plot
showing pairwise Spearman’s rank correlation between clinical severity, pMN and S-specific antibody assays. Darker and larger points indicate stronger correlations.
Blue indicates positive and red indicates negative correlations. Assays are ordered by hierarchical clustering so that assays with similar relationships are together.
(C) Correlation plot showing pairwise Spearman’s rank correlation between clinical severity, intracellular neutralization and N-specific antibody assays. Darker and
larger points indicate stronger correlations. Blue indicates positive and red indicates negative correlations. Assays are ordered by hierarchical clustering so that assays
with similar relationships are together.November 2021 | Volume 12 | Article 748291
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results in these particular individuals.
A more detailed analysis of the data revealed a very strong
correlation between clinical severity score and nAb (Figure 3,
Spearman’s rank correlation = 0.71). As previously indicated in
Section 3.1, the majority of hospitalised patients (clinical scores > 4)
presented very high nAb levels, the majority above 200 IU/ml, and
in some cases reached values as high as 2117 IU/ml. However, two
patients’ samples, those from patients, 37 and 50, had levels of nAb
as low as 0.63 and 11 IU/ml respectively. These samples also had
low values in the ELISA and Luminex assay as discussed in the
previous section. Patient 17 presented low antibody levels by both
assays but remain above the positive threshold and consistent with
this, presented moderate nAb levels (74 IU/ml). Consistent with the
correlation observed between severity and nAb levels, patients 17, 37
and 50 had clinical scores of 1 and 2.
The nAb data distribution in infected HCW is more widespread,
ranging between 0.426 to 2092 IU/ml, including asymptomatic cases
of COVID-19 (clinical score of 1) to moderate pneumonia with
Sp>90% (clinical score of 3). Some of the samples had nAb levels as
high as those observed in most severe cases of COVID-19. As
expected, the seronegative group of HCW presented very low nAb
levels ranging between 0.426 to 18 IU/mlwith clinical scores of 1 or 2.
3.6 SARS-CoV-2 Antigen Display by
Automated Microfluidics Western Blot
Analysis
In order to dissect the specificity of the antibody response to Spike
(S) and nucleoprotein (N) of SARS-CoV-2 and to identify
additional candidate biomarkers of immunity, we used a semi-
automated immunoblotting assay (Jess, Protein Simple, Biotechne)
based on the separation of protein antigens in a polyacrylamide gel
matrix contained in a capillary tube. This microfluidics assay
sequentially processed diluted plasma samples, conjugated
antibodies, washing buffers and chemiluminescent reagents
sequentially through microfluidics. A final chemiluminescent
reaction is read by the device and translated into a luminometryFrontiers in Immunology | www.frontiersin.org 9intensity signal which can be analysed quantitatively. The results are
visualised as traditional western blotting lane format or analytically
the data outputs as densitometric units for quantitative antigen
specific responses. We utilised this assay qualitatively (immuno-
blotting images) and quantitatively (using total luminometry units)
to screen and confirm antibody specific responses to the intact Spike
protein and its subunits, S1, S2, and RBD as well as the SARS-CoV-
2 N antigens. Furthermore, antibody isotype (IgM, IgG, and IgA)
and IgG subtype responses (IgG1 to 4) were measured.
3.6.1 Quantitative Data
The results of IgG responses (Figure 4) were consistent with the
findings described above for the antigen binding assays (Luminex,
Lateral Flow, ECLIA and ELISA assays). The IgG antibody
responses of COVID-19 patients showed significantly higher
median Chemiluminescent Intensity Units (CIU) values than
those of seropositive HCWs. Of note is the wide range of N-
specific and S-specific IgG CI measurements, of both patients and
seropositive HCW.
For the most part, the results of the IgA antibody immuno-
blotting mirrored those of the IgG responses although the median
CIU was significantly lower than for IgG, with values below 10,000
CIU as opposed to the IgG values for the same antigen in the range
of 300,000 CIU. The IgA responses to the Spike subunits, RBD, S1
and S2 of seropositive HCWs against N and Spike were markedly
lower than those exhibited by the IgG responses while not
surprisingly, IgM responses were heterogeneous in this cross-
sectional convalescent study, presenting negative or close to ‘0’
median CIU values for all three cohorts against all five antigens.
Although the time of sampling was approximately 3-5 months
following exposure or hospitalisation, IgM was clearly detected in a
very few individuals.
3.6.2 Qualitative Data – Antigenic Specificity of the
Antibody Response
Analysis of the immuno-blotting electropherograms revealed
that the relative antigen response of individual sera wasA B
FIGURE 3 | pMN virus neutralisation in International Units by cohort and COVID-19 severity. (A) Boxplot showing the difference between cohorts. (B) Scatterplot
showing neutralisation against disease severity. The dotted line shows the 95% upper CI calculated from pre-pandemic sera, 5.9 International Units.November 2021 | Volume 12 | Article 748291
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distinct patterns of antigen specific responses. Representative
results of these patterns are presented in Figure 5. Most patients’
samples showed equally strong IgG reactivities against bothNandS
antigens (High N=S). However, a number of samples displayed
weaker signals against both antigens (patients p17, p37, p50) (Low
N=S), whereas some presented predominantly an anti-N reactivity
(p40) (N>S) and some had predominantly anti-S-specific
antibodies (p8) (N<S) (Figure 3B). This heterogeneity of the
antigen specificity of the IgG response was also evident in the
results of seropositive HCW samples. Again, these four categories
could be distinguished according to N/S ratios: a) N = S (high)
(HCW 361.1); b) N > S (HCWs s24.1, s25.1, s38.1, s38.2, s117.1,
s224.1, s414); c) N < S (HCWs s249.1, s408) and d) N = S (low)
(HCWs s4.1, s198.1, s223.1, 254.1, s286.1, s418.1, s423.1, s439.1).
Similarly, these patterns were also identified in the IgA responses,
although uniformly lower than the IgG responses in all individuals,
especially in the seropositive HCW.
There were very few samples giving a positive result in the IgM
immuno-blotting assay and this signal was very low in magnitude
except for one sample in each of the cohorts. For this reason the
antigenic specificity patterns of the IgM response differed
significantly from the IgG and IgA responses. Most positive IgM
samples in the patient cohort were N-specific (n=7), albeit the
detection signal of the electropherogram was weak in 6 of them,
and only one of the samples also had an S-specific IgM signal.
Some of the seropositive HCW samples detected the Spike (s25.1,
s308.1 and s398.1) and its subunits RBD, S1, S2 (s398) as well as NFrontiers in Immunology | www.frontiersin.org 10(s398 and s418). One sample presented a strong N response
(HCW s418) suggestive of a recent exposure to SARS-CoV-2 or
to a common cold coronavirus which was not detected by the
primary screening serological tests used in this study.
3.7 Intracellular Neutralisation Assay
(EDNA)
To explore the potential use of biomarkers indicative of TRIM-
21 based mechanisms of immunity we applied the EDNA assay
to our cohorts’ samples. We electroporated Vero ACE2/
TMPRSS2 cells with sera from each patient and seropositive
HCW and ten seronegative HCW samples for reference. In the
presence of electroporated N-binding antibodies, virus
replication was inhibited. The results of these analyses
(Figure 6) indicate that patients’ sera are more effective at
inhibiting virus replication than sera from the seropositive
HCW. All but one patients’ samples were positive by the
EDNA (Figure 6B). In contrast, some seropositive HCW
tested negative or produced a low positive result (Figure 6C),
whereas all tested seronegative HCW did not affect virus
replication, as expected (Figure 6D). Interestingly, patients and
seropositive HCW samples with the strongest inhibition of virus
replication had the highest levels of anti-N antibodies such as
s414 or p32, confirming that the observed intracellular
neutralisation is mediated by anti-N antibodies. Importantly,
these results highlight that traditional neutralization assays, fail
to measure the potential contribution of anti-N antibodies
present in SARS-CoV-2 positive sera.FIGURE 4 | IgG, IgA and IgM responses against Spike, RBD, S1, S2 and N antigens of SARS-CoV-2. The image displays the Median Chemiluminescence
Intensities of antigen-specific IgG (top), IgA (middle) and IgM (bottom) of seronegative HCWs (left), seropositive HCWs (middle) and COVID-19 patients (right). A panel
of pre-pandemic sera was used to calculate the negative cut-off value for each antigen (mean + 2STD) and then subtracted from the chemiluminescent signal of
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FIGURE 5 | Representative electropherograms of IgG, IgA and IgM antibody responses to Spike, RBD, S1
specific IgG (A, D, G), IgA (B, E, H) and IgM (C, F, I) antibody reactivities of seropositive HCWs (left panel),
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The ‘Humoral Immune Correlates of COVID-19 Project (HICC)’
(https://www.hicc-consortium.com/) was established to identify
humoral biomarkers of immunity and develop standardised
assays to determine the thresholds of antibody responses that
correlated with protection against SARS-CoV-2 infection or with
severe COVID-19 disease requiring hospitalisation. Before
conducting serological analysis of vaccine breakthrough or re-
infection cases with which to define correlates of protection we
wanted to define first those candidate antibody biomarkers by
cross-platform comparison of a range of antibody-based assays,
such as nAb and SARS-CoV-2 antigen-specific (N-, S-, S1-
S2- N- and RBD) binding antibodies (Pan-Ig, IgG, IgM, IgA)
in convalescent serum or plasma samples from COVID-19
hospitalised patients and seropositive and seronegative HCW
(Table 3). The main findings of the present study confirmed: a)
that there is a strong positive correlation between clinical severity
and SARS-CoV-2-specific antibodies; b) that there is a strong
correlation between nAb and S- and RBD-specific antibody
levels; c) that intracellular neutralisation correlated very well
with N-specific antibody levels; and d) that there are different
antigen-specific reactivity patterns of IgG, IgA and IgM in
seropositive samples. We used the WHO International
Standard (NIBSC 20/136) to quantify some of these antibody-
based parameters in International Units (IU) for neutralisation
assays and Binding Antibody Units (BAU) for ELISA. The
adoption of common results reporting unitage in IU and BAUFrontiers in Immunology | www.frontiersin.org 12as those described in this study would eventually facilitate
comparative analyses of data generated by immunogenicity
studies performed by different teams in different parts of
the world.
The criteria for the serological classification of the convalescent
samples used in this study were based on a UKAS-accredited
Luminex assay benchmarked for COVID serological screening
(33) and another two well-stablished serological assays (AccuTell
lateral flow IgG/IgM; Roche ECLIA) (30, 40, 41). The results of
these tests were consistent with other additional tests (pan-Ig N
and RBD ELISA; immuno-blotting) described in this paper. As
expected, only samples with low antibody levels produced some
discrepancies due to the positive-negative cut-off of each particular
assay. Such discrepancies could also be due to the previously
described cross-reactivity between the N antigens of SARS-CoV-2
and the seasonal human common cold coronaviruses (42) which
was also consistent with our analysis of pre-pandemic
serum samples.
Consistent with published data (8, 11, 43, 44), we found a very
strong correlation between nAb, as measured by the pMN assay,
and severity of disease. Evidence from epidemiological studies and
vaccine clinical trials indicated that nAb correlate with immunity
against COVID-19 (45, 46). However, knowledge of the early
immunopathologic events that trigger severe COVID-19 disease is
still incomplete, in particular the role of complement system its
interaction with early antibody responses.
Various studies indicate that the high nAb levels found in
severe COVID-19 patients are a consequence of the high andA B
C D
FIGURE 6 | Intracellular neutralisation data from EDNA assay. The results are expressed in genome copies relative to 18S and percentage normalised to PBS. Panel
(A) depicts median values of EDNA results of the three cohorts, expressed as Fold neutralisation relative to PBS; Panels (B–D) correspond to individual EDNA results
of patients, seropositive HCW and seronegative HCW respectively.November 2021 | Volume 12 | Article 748291
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expression of viral antigens in the host, or alternatively, a
consequence of a dysregulated immune response leading to
antibody-mediated immunopathology. Studies by Garcia-
Beltran and co-workers suggested the latter and that the
antibody response profile in severe patients, characterised by
high nAb to IgG-RBD ratios, is a consequence of such
dysregulation. These authors suggested that the use of specific
antibody response metrics could be useful to discriminate
between immuno-pathological antibody responses from those
that would lead to protective immunity. Our study does not
address this question but proposes different antibody-based
assays, parameters and standardised methods that could
facilitate comparative data analysis of humoral immunity. Use
of these antibody response metrics could be applied to serum or
plasma samples in vaccination efficacy/efficiency or re-infection
studies in order to elucidate thresholds of protective immunity.
COVID-19 serological studies published to date show a
positive correlation between Spike-specific antibodies and nAb
(47). Accordingly, our study showed that nAb of COVID-19
convalescent sera correlated very strongly with Spike-specific
IgG and IgA binding antibodies. This can be potentially very
advantageous for assessing protective immunity in clinical trials
or in immuno-surveillance programmes, as evidence supporting
the use of nAb as a biomarker of COVID-19 immunity continues
to grow (48). Indeed, some of the S-specific antibody binding
assays used in our study are quantitative, reproducible, suitable
for calibration to the international standard and high-
throughput. The latter is a distinct advantage over the more
laborious and time-consuming neutralisation assays. However,
validity of these correlations need further evaluation as other
reports indicate the importance of IgM and IgA contribution to
virus neutralisation, and that the nAb/IgG ratio correlate with
30-day survival (11).
Our data also showed a strong correlation between nAb,
disease severity and N-specific IgG and IgA antibody levels in
convalescent samples. The intracellular neutralisation dataFrontiers in Immunology | www.frontiersin.org 13generated by the EDNA assay represents an indirect evidence
that the TRIM-21 mediated mechanism of immunity could play
a relevant role in protection against COVID-19. The output of
the EDNA assay from SARS-CoV-2 infected cells previously
electroporated with serum from patients or HCW showed a
significant reduction of virus replication. This was proportional
to the N-specific antibody levels of the sera. Previously, it has
been shown that antibody-antigen complexes are rapidly
degraded in the cytosol by TRIM21 and the proteasome (17,
49). If N protein is degraded inside an antigen presenting cell,
this provides peptides for MHC-I presentation. Indeed, studies
have shown that cytotoxic T-cell immunity to virally-infected
cells requires internalization and cross-presentation of virus-
antibody complexes by dendritic cells (50). It has been previously
shown that TRIM21 uses anti-N antibodies to degrade the
nucleoprotein of LCMV, promote cytotoxic T-cells and clear
mice of infection (18). As indicated earlier, longitudinal analyses
of antibody levels from patients and HCWwill help to determine
the relevance of this anti-SARS-CoV-2 immunity mechanism
and how N-specific antibodies might contribute to either
protective immunity or immuno-pathology. Here we provided
experimental evidence that sera from COVID-19 convalescent
patients and seropositive HCW, but not those from seronegative
HCW, neutralised effectively SARS-CoV-2’s infectivity
intracellularly and that these measurements correlated very
strongly with anti-N antibody levels (Figure 2).
The analysis of the antigen specificity of serum IgG and IgA of
patients and HCW showed an overall immuno-dominance of N-
and S-specific antibodies over S1, S2 and RBD antigens.
However, we observed, consistent with other studies (51), that
the N/S ratios were not always homogeneous. Further analyses of
the evolution of antigen-specific antibody responses of our
cohorts over time will help to interpret the relationships
between these metrics and the clinical outcome of SARS-CoV-
2 infection.
Our data indicate that serum IgA responses paralleled those
of IgG in terms of antigen specificity, albeit the magnitude isTABLE 3 | Summary of the main features of the antibody-based assays used in this study.
Antibody assays Isotype/
Sub-isotype
Functional Turnaround Throughput Suitable for Standardisation
(WHO Standard)
Potential to derive a
Correlate of Protection
Pan Ig ELISA - N IgG+IgA+IgM No 24 hours Medium Yes Unknown
Pan Ig ELISA - S IgG+IgA+IgM No 24 hours Medium Yes Possible
ECLIA (total Antibody) - N IgG+IgA+IgM No 24 hours Medium-
High
Likely Unknown
ECLIA (total antibody) - S IgG+IgA+IgM No 24 hours Medium-
High
Likely Possible
Multiplexed Bead Flow Cytometry –
Luminex (IgG/IgA/IgM)
IgG/IgA/IgM No 6 hours Medium-
High
Potentially Possible
Semi-automated Immunoblotting IgG/IgA/IgM No 4 hours Medium-
High
Potentially Possible
Lateral Flow IgG/IgM IgG/IgM No 30 mins Low No No
EDNA N/A Yes; TRIM-21
mediated CTL
48 hours Low Not possible at the moment Unknown
pMN N/A Yes; Virus
neutralisation
48 hours Low Yes Reasonably likelyNovember 2021 | VIgG+IgA+IgM, indicates the three isotypes are detected simultaneously in the assay. IgG/IgA/IgM, indicates that each isotype generates a separate reading.olume 12 | Article 748291
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component of the immune response against COVID-19 (52, 53)
as it contributes to virus neutralisation (54). Interestingly, studies
have stablished a correlation between serum IgA levels and
severity, with mild COVID-19 cases, such as those occurring in
the young, showing secretory IgA responses with little detection of
IgA in serum (55). In our study we have found IgA in convalescent
samples collected 3-5 months post-infection but consistent
with Sterlin’s findings (54) the levels were significantly reduced
relative to IgG titres. However, Varadhachary and co-workers
(53) have detected peak IgA levels in saliva at 3 months post-
infection suggesting the kinetics of IgA in serum and mucosal
surfaces are different. In our study we did not measure mucosal
IgA and thus we were unable to establish their correlation
with serum IgA but further efforts should be aimed at
elucidating how these two isotypes evolve in time in different
body compartments in order to define an IgA-based biomarker
of protection.
After a viral infection, IgM responses are usually the first to
appear in serum and this is the case too for COVID-19 (56, 57).
Our data indicates that IgM are easily detected only in a few
individuals from the patients and seropositive HCW cohorts.
Some studies report IgM lasting up to at least 3 months post-
infection (56, 58) and it is therefore not surprising that IgM was
detected in some of our convalescent samples.
A cornerstone of our study was the use of the WHO
International Standard for anti-SARS-CoV-2 immunoglobulin
(20/136) to benchmark neutralising antibody responses and to
relate other binding assays to our findings with this standard. We
expressed in International Units (IU) and Binding Antibody Units
(BAU) the results of the most commonly used serological assays
(25). The objective of this approach was to adopt the WHO
International Standard unitage to quantify the levels of cardinal
serological (antibody) biomarkers of COVID-19 immunity in
order to facilitate cross-comparison of immunogenicity data,
which ultimately will facilitate the derivation of Correlates of
Protection against COVID-19. This may become increasingly
important for bio-regulatory approval of SARS-CoV-2 vaccines
in future months. Indeed, the emergence and rapid spread across
the globe of COVID-19, prompted the rapid development of
vaccines against this disease. However, the vast amount of
scientific data arising from clinical trials and epidemiological
studies addressing COVID-19 immunity have not yet translated
into an unequivocal definition of a reliable CoP. The vaccines that
are now being used across the globe were licensed on the basis of
vaccine efficacy data obtained in placebo controlled clinical trials.
These are very costly and they depend on the rates of natural
infections occurring in the populations to which the vaccinated
participants belong. However, more vaccines are needed to meet
the global public health demands, even more so with the
emergence of SARS-CoV-2 variants of concern with proven
ability to escape the antibody responses developed against
vaccines or previous infections (https://www.sciencedirect.com/
science/article/pii/S0092867421002981). But the exposure of
participants to natural infections in placebo-controlled clinical
trials, are increasingly difficult to justify. Furthermore, recruitmentFrontiers in Immunology | www.frontiersin.org 14of seronegative volunteers will become more and more
complicated with the continuing rise of SARS-CoV-2
seroprevalence in the global human population. In these
circumstances, non-inferiority clinical trial designs and
immuno-bridging using an existing vaccine as a comparator
would seem to be favoured. The definition of a CoP in
International Units would help assess clinical efficacy of
COVID-19 vaccines on the basis of analyses of immunogenicity
data, rather than relying on evaluating clinical efficacy. Recent
studies point to nAb as a reliable indicator of vaccine induced
immunity (48). However, the majority of these studies used
disparate assays and units to define antibody protection
thresholds. The use of an International Unit for this purpose
would enable comparative analyses of immunogenicity data to be
made facilitating the derivation of CoP. It is important to note,
that theWHO International Standard is not intended to be used as
a day-to-day reagent, but rather, as a primary calibration reagent
against which secondary standards should be calibrated. Thus, in
our study, we calibrated our HICC sera against theWHO standard
and used these HICC sera as our secondary calibration reagents to
derive the unitage of the samples we tested in our assays.
In conclusion, we have identified a range of assays and
biomarkers of COVID-19 immunity that will be used to define
CoP in future studies using serum and plasma samples
sequentially collected from these or similar cohorts, or notably,
from vaccination breakthrough or re-infection cases. Such
studies would need to extend their focus to SARS-COV-2
variants of concern that have been emerging since the
beginning of the pandemic. The emergence of these strains
with enhanced transmissibility, pathogenicity and antigenicity
represents another challenge for vaccine manufacturers and
regulators, and developing methods for standardising assays
for comparison of Nab against VOC should be a priority.DATA AVAILABILITY STATEMENT
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